<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093506</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2011-098</org_study_id>
    <nct_id>NCT03093506</nct_id>
  </id_info>
  <brief_title>Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance</brief_title>
  <official_title>Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent study by Plenge et al. revealed that rhEpo treatment enhances skeletal muscle
      mitochondrial respiratory capacity in humans indicating a muscle ergogenic effect of rhEpo on
      aerobic metabolism. The main purpose of the present study is to determine if a shorter
      treatment period with micro-dose as well as low-dose rhEpo has similar effects on muscle
      mitochondrial function.

      Higher doses of rhEpo is known to increase cognitive performance, but it is not clear if
      lower doses of rhEpo have similar effects. A second purpose of the present study is to
      determine if micro-dose as well as low-dose rhEpo increases cognitive performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-five healthy young male volunteers are randomized to either a low-dose rhEpo (60
      IU/kg/week), micro-dose rhEpo (20 IU/kg/week), or placebo control (saline) group. All
      subjects receive two subcutaneous injections per week for four weeks. Muscle biopsies are
      taken at the beginning and end of the study period. Mitochondrial function is measured in
      permeabilized fibres using high-resolution respirometry with the substrates malate (2mM),
      octanoyl carnitine (1.5mM), glutamate (10mM), succinate (10mM), under saturating [ADP] (5mM),
      and with the membrane uncoupler FCCP (1Î¼M).

      On the first day before administration of rhEpo and after the four weeks' treatment the
      subjects are undergoing two cognitive performance-tests, Raven Standard Progressive Matrices
      (Raven), and Number Finder (NUFI). Weekly semi-structured interviews are conducted by a
      blinded interviewer focusing on experienced change in cognitive performance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal oxygen-flux (picomol/second)</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of speed-score and accuracy-score in the RAVEN-test</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of correctly found fields in the NUFI-test</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of the interviews on a scale from -3 to +3 according to experienced change in ability to concentrate</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Human Volunteers</condition>
  <arm_group>
    <arm_group_label>Low-dose rhEpo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RhEpo 60IU/kg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micro-dose rhEpo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RhEpo 20IU/kg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose rhEpo</intervention_name>
    <description>60IU/kg/week</description>
    <arm_group_label>Low-dose rhEpo</arm_group_label>
    <other_name>Recombinant Human Erythropoitin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micro-dose rhEpo</intervention_name>
    <description>20IU/kg/week</description>
    <arm_group_label>Micro-dose rhEpo</arm_group_label>
    <other_name>Recombinant Human Erythropoitin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal medical examination

          -  Weekly exercise for 0-5 hours

        Exclusion Criteria:

          -  Smoking daily

          -  Earlier use of performance-enhancing drugs

          -  Elite athletes

          -  Presence of cardiovascular or metabolic disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soeren L. Larsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital Bispebjerg, Department of Anaesthesiology</name>
      <address>
        <city>Copenhagen</city>
        <state>Kbh NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R. Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol. 2012 Mar 13;3:50. doi: 10.3389/fphys.2012.00050. eCollection 2012.</citation>
    <PMID>22419911</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Soeren Lundgaard Larsen</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Human volunteers</keyword>
  <keyword>Mitochondrial function</keyword>
  <keyword>Cognitive performance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

